Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma

Trial Profile

Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs PU H71 (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
    • 14 May 2014 Planned primary completion date changed to 1 Apr 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top